Establishment Labs(US:ESTA)2025-08-07 12:06Revenue and Guidance - Total revenue for Q2 2025 was $51.3 million, a 16.3% increase from $44.1 million in Q2 2024[4] - US Motiva sales contributed $10.3 million to the total revenue in Q2 2025[5] - 2025 revenue guidance increased to $208 million to $212 million, reflecting a year-over-year growth of 25%–28%[5] Profitability and Loss - Gross margin for Q2 2025 was 68.8%, up from 65.6% in Q2 2024[5] - Loss from operations in Q2 2025 was $14.1 million, compared to a loss of $9.3 million in Q2 2024[5] - Adjusted EBITDA loss for Q2 2025 was $8.5 million, compared to a loss of $4.1 million in the same period last year[5] - Net loss for the three months ended June 30, 2025, was $16.593 million, compared to a net loss of $17.181 million for the same period in 2024, showing an improvement of approximately 3.4%[24] - Adjusted EBITDA for the six months ended June 30, 2025, was $(20.626) million, compared to $(8.099) million for the same period in 2024, indicating a decline in performance[24] Cash Flow and Liquidity - Cash use in Q2 2025 was $14.5 million, down from $18.4 million in Q2 2024[5] - Cash balance as of June 30, 2025, was $54.6 million, with total cash including credit line at $79.6 million[5] - The company aims to achieve positive EBITDA in 2025 and become cash flow positive in 2026[3] - Cash and cash equivalents decreased from $90.347 million to $54.639 million, a reduction of approximately 39.5%[22] Expenses and Assets - R&D expenses decreased to $5.2 million in Q2 2025 from $5.5 million in Q2 2024, primarily due to lower clinical trial expenses[8] - Total assets decreased from $346.831 million as of December 31, 2024, to $329.668 million as of June 30, 2025, representing a decline of approximately 4.9%[22] - Current liabilities increased from $68.278 million to $80.742 million, marking a rise of about 18.3%[22] Inventory and Receivables - Accounts receivable increased from $65.002 million to $70.092 million, reflecting an increase of about 7.4%[22] - Inventory rose from $78.766 million to $94.683 million, representing an increase of approximately 20.2%[22] Shareholders' Equity and Interest - Total shareholders' equity decreased significantly from $53.095 million to $22.763 million, a decline of about 57.1%[22] - Interest expense for the three months ended June 30, 2025, was $5.956 million, compared to $5.186 million in 2024, an increase of approximately 14.8%[24] Foreign Currency Impact - Foreign currency gain for the three months ended June 30, 2025, was $4.985 million, compared to a loss of $2.764 million in 2024, indicating a positive shift in foreign currency impact[24]